$SLS

10 Health Care Stocks Whale Activity In Today’s Session - SELLAS Life Sciences Gr (NASDAQ:SLS), Zoetis (N

Benzinga reports unusual options activity in 10 healthcare stocks. Notable trades include bullish calls on SELLAS Life Sciences (SLS) at $30 strike, bearish calls on Zoetis (ZTS) at $85 strike, and bullish puts on Lilly (LLY) at $1260 strike. Other stocks with notable activity include NBIX, AGEN, BBIO, BSX, NVO, and CAPR.

Original reporting
Published Aug 21, 2026, 5:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 7:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
10 Health Care Stocks Whale Activity In Today’s Session - SELLAS Life Sciences Gr (NASDAQ:SLS), Zoetis (N — source image
Decision brief

The 30-second read

$SLSBullishLow
01

Why it matters

The mixed bullish and bearish sweeps suggest no uniform market bias for the sector, but individual stocks may experience short‑term moves.

02

Market read

Unusual options activity provides potential short‑term trading signals for the listed healthcare stocks.

03

What to watch

Liquidity constraints and market maker hedging could drive the sweeps without underlying price moves.

Relevance 4/10Novelty 4/10Timing: today's session

Background

Benzinga's automated options scanner flagged unusual activity across ten healthcare stocks during the trading day.

Company-level read

Ticker impact

$SLSBullishMedium confidence
Context

Unusual bullish call sweep on SLS with 200 contracts at $30 strike, indicating potential upside pressure.

Expected impact

Modest short‑term upside if buying continues.

Evidence & confidence

Large call volume and bullish sentiment suggest traders expect a move higher.

$ZTSBearishMedium confidence
Context

Bearish call activity on ZTS with 897 contracts at $85 strike, implying downside expectations.

Expected impact

Potential short‑term dip.

Evidence & confidence

High call volume with bearish sentiment signals traders betting on a decline.

$HIMSNeutralLow confidence
Context

Neutral call sweep on HIMS expiring today, 100 contracts at $30 strike.

Expected impact

Little immediate impact.

Evidence & confidence

Neutral sentiment and small volume suggest no clear direction.

$NBIXBearishMedium confidence
Context

Bearish call trade on NBIX with 98 contracts at $150 strike, long‑dated expiration.

Expected impact

Slight downside risk.

Evidence & confidence

Bearish sentiment on a deep‑out‑of‑the‑money call indicates caution.

$AGENBullishMedium confidence
Context

Bullish call sweep on AGEN expiring today, 150 contracts at $6 strike.

Expected impact

Potential short‑term lift.

Evidence & confidence

Large bullish call volume on the day suggests optimism.

$LLYBullishMedium confidence
Context

Bullish put sweep on LLY with 38 contracts at $1,260 strike, indicating protective buying.

Expected impact

Possible stability or modest upside.

Evidence & confidence

Bullish put sentiment often reflects hedging for a higher price.

$BBIOBearishMedium confidence
Context

Bearish call trade on BBIO, 27 contracts at $70 strike.

Expected impact

Short‑term downside risk.

Evidence & confidence

Bearish sentiment on a near‑term call suggests expectations of a fall.

$BSXBullishMedium confidence
Context

Bullish call sweep on BSX with 84 contracts at $50 strike.

Expected impact

Potential short‑term rally.

Evidence & confidence

Large bullish call volume indicates optimism.

Market effects

Healthcare sector shows varied option sentiment, indicating divergent short‑term expectations.

US market focus; no broader regional effect noted.

Limited to US-listed healthcare stocks.

Counterpoint

High option activity may be speculative noise rather than a true directional signal.

Key entities

  • Sellas Life Sciences

    Ticker SLS, subject of bullish call sweep.

  • Zoetis

    Ticker ZTS, subject of bearish call sweep.

Related articles

$NVOHighAI 8/10

NVO Stock Jumps 4% As European Committee Backs Novo’s Haemophilia Pen

Novo Nordisk (NVO) shares rose 4% after a European Medicines Agency panel recommended approval for Frehemgo, a haemophilia A treatment. Trial data showed patients could switch from rival therapies without a waiting period. The company expects EU launches in Q4 2026, with a U.S. application under review. Frehemgo is designed to mimic factor VIII and is offered in a single-use pen with flexible dosing options.

$NVOHighAI 9/10

Novo Nordisk's FREHEMGO Gets Positive CHMP Opinion For Haemophilia A

Novo Nordisk (NVO) announced a positive CHMP opinion for FREHEMGO (denecimig) to treat haemophilia A. The recommendation is based on the FRONTIER clinical trial program, which showed significant reductions in bleeding rates. NVO plans to launch FREHEMGO in Europe in late 2026, with U.S. submission expected in 2025. The stock is up 3.11%, trading at $43.03.

$NVOMedAI 8/10

Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophili

Novo Nordisk's FREHEMGO® (denecimig) received a positive opinion from the CHMP for EU approval to treat haemophilia A, with or without inhibitors, in adults and children. The drug offers flexible dosing options and is expected to launch in the EU in Q4 2026. The recommendation is based on the FRONTIER trial program, which showed significant reductions in bleeding rates.